Clinician agreement and influence of medication‐related characteristics on assessment of polypharmacy

Abstract

It is not known how clinicians assess polypharmacy or the medication‐related characteristics that influence their assessment. The aim of this study was to examine the level of agreement between clinicians when assessing polypharmacy and to identify medication‐related characteristics that influence their assessment. Twenty cases of patients with varying levels of comorbidity and polypharmacy were used to examine clinician assessment of polypharmacy. Medicine‐related factors within the cases included Beers and STOPP Criteria medicines, falls‐risk medicines, drug burden index (DBI) medicines, medicines causing postural hypotension, and pharmacokinetic drug–drug interactions. Clinicians were asked to rate cases on the degree of polypharmacy, likelihood of harm, and potential for the medication list to be simplified. Inter‐rater reliability analysis, correlations, and multivariate logistic regression analyses were conducted to identify medicine factors associated with clinicians' assessment. Eighteen expert clinicians were recruited (69.2% response rate). Strong agreement was observed in clinicians' assessment of polypharmacy (intraclass correlation coefficients [ICC] = 0.94), likelihood to cause harm (ICC = 0.89), and ability to simplify medication list (ICC = 0.90). Multivariate analyses demonstrated number of medicines (P < 0.0001) and DBI scores (P = 0.047) were significantly associated with assessment of polypharmacy. Medicines associated with harm were significantly associated with the number of medicines (P = 0.01) and Beers criteria medicines (P = 0.003). Ability to simplify the medication regimen was significantly associated with number of medicines (P = 0.03) and medicines from the STOPP criteria (P = 0.018). Among clinicians, strong consensus exists with regard to assessment of polypharmacy, medication harm, and ability to simplify medications. Definitions of polypharmacy need to take into account not only the numbers of medicines but also potential for medicines to cause harm or be inappropriate, and validate them against clinical outcomes.

The Evaluation of Relationship Between Polypharmacy and Anticholinergic Burden Scales

“…DBI is an evidence-based tool used to evaluate a patient’s cumulative exposure to anticholinergic and sedative medicines [ 17 ]. Recently, it was reported that number of medicines and the DBI scores were positively associated with evaluation of the level of polypharmacy [ 38 ]; on the other hand, population and methodology of this study are different from ours.…”

Identification of behaviour change techniques in deprescribing interventions: a systematic review and meta‐analysis

“…Other studies reported a lower acceptance rate of pharmacist recommendations, between 15% and 28% of recommendations enacted on. Recent research has demonstrated a high level of agreement between prescribers and pharmacists in the assessment of potential target medications for deprescribing . In contrast, other research studies indicate that acceptance rates for recommendations made by pharmacists are lower than those made by their physician colleagues .…”

Medication-related quality of life among Ethiopian elderly patients with polypharmacy: A cross-sectional study in an Ethiopia university hospital

“…The definition of polypharmacy has been a point of uncertainty. Ong GJ et al study has determined that there has been an agreement among clinicians on the assessment of polypharmacy and its impact to cause harm to the patient,and other additional factors such as quality of prescription addition to the number of medication can contribute to patient health outcome in addition to the number of medications[4].…”